Curis (NASDAQ:CRIS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Curis (NASDAQ:CRIS) from a strong sell rating to a hold rating in a report released on Saturday morning.

Several other research analysts have also recently weighed in on CRIS. HC Wainwright reiterated a “buy” rating on shares of Curis in a report on Monday, August 17th. Zacks Research lowered Curis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $43.00.

Curis Stock Performance

Curis stock opened at $1.58 on Friday. The business has a 50-day moving average of $4.99 and a 200-day moving average of $11.00. Curis has a 1 year low of $1.50 and a 1 year high of $39.00. The firm has a market capitalization of $3.30 million, a P/E ratio of -0.11 and a beta of 3.13.

Curis (NASDAQ:CRIS) last issued its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 2,365.94%. Research analysts anticipate that Curis will post -24.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Curis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new stake in Curis during the second quarter worth about $1,033,171,000. BlackRock Inc. acquired a new position in shares of Curis during the second quarter worth $28,000. XTX Topco Ltd bought a new position in Curis in the 4th quarter valued at approximately $26,000. Squarepoint Ops LLC lifted its holdings in shares of Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.